Article

SOLA named first Zeiss Vision Premier Transitions Lab

Hebron, NY-Carl Zeiss Vision LLC and Transitions Optical Inc. named SOLA Technologies as the first Carl Zeiss Vision Premier Transitions Lab during a ceremony held recently at SOLA headquarters.

Hebron, NY-Carl Zeiss Vision LLC and Transitions Optical Inc. named SOLA Technologies as the first Carl Zeiss Vision Premier Transitions Lab during a ceremony held recently at SOLA headquarters.

Planned as an annual tribute, the award honors the Carl Zeiss Vision Lab that demonstrates the strongest commitment to growing its business with Transitions Lenses over the previous year.

"The dedication shown by SOLA Technologies in making Transitions such an integral part of its education and promotional initiatives clearly sets the lab apart, and we couldn't ask for a more deserving contender to be the first to claim this prestigious award," Perez continued.

Dave Delle Donne, marketing North America, Carl Zeiss Vision, added, "Since many Carl Zeiss Vision labs are really growing their businesses by partnering with Transitions, we felt compelled to showcase some of their best practices and recognize them for their creativity, dedication and success."

Michael Browning, regional director of lab operations, SOLA Technologies, accepted the award from James Roberts, senior account manager, Transitions. Browning commended the lab's employees as key to its success in 2005, a record year, which showed an increase of more than 40% in sales of Transitions Lenses over 2004.

"Everyone on our lab team has contributed to the success and significant growth in Transitions this year, and shares in today's excitement with this achievement," Browning said.

"We believe in building our business through education and training, and Transitions has been an outstanding partner in arming us with resources and quality sales representative partners to help us perform at our best," he added.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.